Use of Bacteria, Bacterial Products, and other Immunoregulatory Entities in Combination with Anti-CTLA-4 and/or Anti-PD-1 Antibodies to Treat Solid Tumor Malignancies
Generated by an autonomous AI research agent — Anthropic Claude Opus 4.7 or OpenAI GPT-5.5, max reasoning effort. Sources cited inline. Full disclosure at /methodology/jhtv-deep-dive.
Indication
solid tumor malignancies
Modality
Monoclonal Antibody
Mechanism
anti-CTLA-4 / anti-PD-1 checkpoint blockade combined with tumor-specific bacteria
Target
CTLA4, PDCD1
rNPV Envelope
Low
-$45.7M
costs +25% · peak −25%
Base
-$35.6M
cumulative PoS 1.3%
High
-$25.5M
costs −25% · peak +25%
This is an illustrative cohort-consistency profile for a bacterial/checkpoint combination method, not a novel antibody. Costs reflect combination oncology trials and bacterial-product CMC; PoS is held down because the asset depends on translating murine bacterial tropism, checkpoint synergy, and safety into humans.
Composite score breakdown
Locked rubric — 40/30/30 weights
Clinical relevance · 40%
0.70
Modality fit · 30%
0.51
Whitespace · 30%
0.50
Composite 0.584 — composite-score rank #33 of 50 top-tier inventions in the jhtv-portfolio@2026-Q2 cohort. The page header uses rNPV rank (#26) to match the index ordering.
Comparators
Real programs anchoring the engine inputs
Anti-CTLA-4 / anti-PD-1 checkpoint blockade plus tumor-targeting bacteria
The direct JHU method: attenuated anaerobic tumor-core bacteria combined with existing checkpoint antibodies to improve metastatic-tumor immune response in murine models.
Criteria 1: exact mechanism from the asset page; not a novel antibody comparator.
Gut microbiome / bacteria plus checkpoint blockade literature
Mechanistic adjacent precedent showing bacteria can modulate anti-CTLA-4 and anti-PD-1 activity. Supports biology but does not create a standalone antibody product.
Criteria 1 and 4: same checkpoint-microbiome interaction, adjacent rather than product-identical.
Nivolumab plus ipilimumab checkpoint combinations
Launched checkpoint-combination backbone that the method would piggyback on. It validates clinical use of the antibodies but also proves this invention is a combination-use method, not a new mAb.
Criteria 2 and 4: clinical checkpoint-combination anchor; used only for pathway context.
Stage profile
Asset-specific cost, duration, and PoS by stage
| Stage | Cost | Duration | PoS | Citations |
|---|---|---|---|---|
| Preclinical | $14.0M | 24 mo | 32.0% | [0] [1] [2] |
| Phase I | $50.0M | 18 mo | 55.0% | [0] [2] |
| Phase II | $125.0M | 30 mo | 22.0% | [1] [2] |
| Phase III | $270.0M | 42 mo | 40.0% | [1] [2] |
| NDA/BLA Review | $15.0M | 12 mo | 84.0% | [2] |
Multiplier handling: Eligible multipliers (combination_immunotherapy_rationale) are already reflected in Day-1 comparator-calibrated PoS. Re-applying them via log-odds stacking would double-count, so per-stage PoS is taken as final. See methodology for the rule.
Peak revenue and discount rate
$200.0M peak · WACC 15.0%
Peak revenue. The academic value path is a licensed combination-use or bacterial-platform partnership, not ownership of Opdivo/Yervoy-like antibody economics. The $200M illustrative peak is a conservative product-equivalent envelope for a niche partnered bacterial adjunct, not a full checkpoint-franchise forecast.
WACC. Bacterial immunotherapy plus checkpoint-combination development carries high translational, safety, and regulatory uncertainty.
Sensitivity (tornado)
Top drivers of rNPV variance
Drivers ranked by absolute rNPV swing. The vertical tick inside each bar marks the base rNPV (-$35.6M); each bar spans the rNPV range produced by flexing one input between its low and high values. Gold = the input pushes rNPV up when increased; red = the input pushes rNPV down when increased.
Monte Carlo distribution
1,000 trials · rpNPV mode
This is a bimodal distribution by construction, not a Gaussian. Most paths terminate in clinical failure (red cluster — accumulated cost only); a minority succeed and capture full peak revenue (green tail). Bar heights are square-root-scaled so the success tail stays visible alongside the much taller failure cluster; exact counts are preserved in the percentiles below. Gold line = median (P50). Navy dashed = base rNPV (mean) — the probability-weighted expected value, which can sit above the median when the upper tail is strong enough to outweigh the failure cluster (and close to the median when it isn’t).
P5
-$137.9M
P25
-$40.4M
P50 (median)
-$14.0M
P75
-$8.6M
P95
-$4.8M
Prob ≥ 0
0.5%
Evidence register
4 per-assumption citations
| Assumption | Source | Date | Confidence |
|---|---|---|---|
JHU asset is a combination method using tumor-targeting bacteria and existing checkpoint antibodies cmo_findings.asset_class_reality | Use of Bacteria, Bacterial Products, and other Immunoregulatory Entities in Combination with Anti-CTLA-4 and/or Anti-PD-1 Antibodies regulatory | 2017-02-24 | high |
CTLA-4 activity depends on gut microbiota comparators[1] | Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota peer_review | 2015-11-27 | high |
Bifidobacterium improves anti-PD-L1 response in preclinical models stage_profile.phase_2.pos | Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy peer_review | 2015-11-27 | high |
Checkpoint pathway clinical anchor comparators[2] | Nivolumab drug information regulatory | 2025-01-01 | high |
Thesis
Why this asset earns its rank
This is not a novel mAb; it is a combination-method / bacterial-immunotherapy discovery using existing anti-CTLA-4 and anti-PD-1 antibodies. The JHU page describes attenuated anaerobic tumor-core bacteria plus checkpoint blockade in murine solid-tumor models. The rNPV envelope is shown only for cohort consistency - the rNPV is not the decision criterion here, which is why the asset is classified partnership_candidate rather than vc_fundable.
Comparator economics confirm that this should be read as an adjunct method. Nivolumab/ipilimumab-type combinations validate the checkpoint backbone, and microbiome-checkpoint papers validate bacterial immunomodulation, but neither grants JHU ownership of a new antibody product. The engine result is -$45.7M to -$25.5M, with a base rNPV of -$35.6M and cumulative PoS of 1.3%; that is a conservative partnered-adjunct envelope, not a checkpoint-antibody revenue forecast.
Verdict: scientifically plausible and potentially partnerable if a live bacterial product and indication are defined, but not investable as a standalone antibody. It earns its rank because the rubric rewarded clinical relevance and mAb-bucket biology, while the CMO reality is a bacterial/checkpoint combination method.
Key risks
Asset-specific, not generic biotech risks
- Asset-class mismatch: the invention uses approved checkpoint antibodies and a bacterial adjunct; there is no novel antibody candidate to value.
- Bacterial-product risk: human safety, biodistribution, clearance, antibiotic rescue, and sepsis controls are central gating items.
- Clinical positioning risk: checkpoint combinations already compete intensely; the bacterial adjunct must show additive benefit in a checkpoint-refractory setting.
- IP/value-capture risk: a method-of-use around existing antibodies is less defensible than owning a drug substance.